May 30, 2025 10:48AM
May 30, 2025 10:47AM
May 15, 2025 04:05PM
May 13, 2025 04:15PM
Apr 23, 2025 09:20AM
Mar 31, 2025 04:05PM
Mar 28, 2025 08:30AM Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
Mar 17, 2025 08:30AM
Mar 9, 2025 10:07PM
Mar 9, 2025 10:06PM
Dec 13, 2024 06:15PM
Nov 14, 2024 04:10PM
Nov 14, 2024 04:10PM
Nov 12, 2024 04:30PM Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Sep 16, 2024 07:32AM
Sep 16, 2024 07:30AM
Sep 4, 2024 08:00AM
Aug 13, 2024 04:05PM
Aug 12, 2024 08:30AM
Jul 25, 2024 07:31AM
Jul 25, 2024 07:30AM Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
Jul 15, 2024 08:00AM
Jul 2, 2024 08:01AM
Jul 2, 2024 08:00AM
Jul 2, 2024 07:03AM
Jul 2, 2024 07:00AM
Jun 24, 2024 07:31AM
Jun 24, 2024 07:30AM Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
Jun 5, 2024 10:00PM
May 31, 2024 09:00PM
May 21, 2024 08:05PM
May 16, 2024 10:00PM
May 15, 2024 04:15PM
May 13, 2024 08:30AM
May 12, 2024 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Checkpoint, Ocugen, and Sonder Innovations and Encourages Investors to Contact the Firm
May 10, 2024 08:30AM
May 7, 2024 09:00PM
May 2, 2024 09:00PM
Apr 28, 2024 09:00PM
Apr 26, 2024 04:56PM
Apr 24, 2024 09:00PM
Apr 20, 2024 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
Apr 16, 2024 09:00PM
Apr 15, 2024 05:14PM
Apr 12, 2024 09:00PM
Apr 8, 2024 09:00PM
Apr 7, 2024 11:21PM
Mar 28, 2024 04:05PM
Mar 22, 2024 08:30AM Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Mar 18, 2024 08:04AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All